Sofosbuvir treatment and hepatitis C virus infection

doi:10.4254/wjh.v8.i3.183

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8061)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

541

WORD

202

HTML

3528

Tables (1-4)

154

Sum=4425

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

432

Download

675

Sum=1107

Publishing Process of This Article

Item

Count

Browse

1061

Download

1468

Sum=2529

Jan 28, 2016 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jan 28, 2016; 8(3): 183-190
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.183

Table 4 Summary of phase 3 study for hepatitis C virus-human immunodeficiency virus co-infected patients

Genotype	Study name	Population	Treatment	Duration (wk)	n	LC (%)	SVR12 (%)
1	PHOTON-1	Naïve	SOF/RBV	12	114	4.4	76
	PHOTON-2	Naïve	SOF/RBV	24	112	15	85
2	PHOTON-1	Naïve	SOF/RBV	12	26	-	88
		Experienced	SOF/RBV	24	24	-	92
	PHOTON-2	Naïve	SOF/RBV	12	19	5	89
		Experienced	SOF/RBV	24	6	33	83
3	PHOTON-1	Naïve	SOF/RBV	12	42	-	67
		Experienced	SOF/RBV	24	17	-	94
	PHOTON-2	Naïve	SOF/RBV	24	57	5	91
		Experienced	SOF/RBV	24	49	47	86
4	PHOTON-2	Naïve	SOF/RBV	24	31	26	84

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; IFN: Interferon; RBV: Ribavirin.

Citation: Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190
URL: https://www.wjgnet.com/1948-5182/full/v8/i3/183.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i3.183